{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:05Z","timestamp":1786979945108,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["55\/4\/13\/CARE-CP\/2018-NCD-II"],"award-info":[{"award-number":["55\/4\/13\/CARE-CP\/2018-NCD-II"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00280-022-04432-4","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T15:15:07Z","timestamp":1650381307000},"page":"751-759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer"],"prefix":"10.1007","volume":"89","author":[{"given":"Khushboo A.","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parsshava","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murari","family":"Gurjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Rane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath","family":"Nookala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8942-0332","authenticated-orcid":false,"given":"Vikram","family":"Gota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"4432_CR1","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1634\/THEONCOLOGIST.2012-0044","volume":"17","author":"GM Blumenthal","year":"2012","unstructured":"Blumenthal GM, Cortazar P, Zhang JJ et al (2012) FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist 17:1108\u20131113. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2012-0044","journal-title":"Oncologist"},{"key":"4432_CR2","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","volume":"13","author":"VL Goodman","year":"2007","unstructured":"Goodman VL, Rock EP, Dagher R et al (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13:1367\u20131373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2328","journal-title":"Clin Cancer Res"},{"key":"4432_CR3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/annonc\/mdv589","volume":"27","author":"S Bracarda","year":"2016","unstructured":"Bracarda S, Iacovelli R, Boni L et al (2016) Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol Off J Eur Soc Med Oncol 27:366. https:\/\/doi.org\/10.1093\/annonc\/mdv589","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"4432_CR4","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1093\/annonc\/mdv357","volume":"26","author":"JL Lee","year":"2015","unstructured":"Lee JL, Kim MK, Park I et al (2015) RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial. Ann Oncol 26:2300\u20132305. https:\/\/doi.org\/10.1093\/annonc\/mdv357","journal-title":"Ann Oncol"},{"key":"4432_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2020.00313\/REFERENCE","author":"H Deng","year":"2020","unstructured":"Deng H, Li M, Wu Q et al (2020) A 2\/1 sunitinib dosing schedule provides superior antitumor effectiveness and less toxicity than a 4\/2 schedule for metastatic renal cell carcinoma: a systematic review and meta-analysis. Front Oncol. https:\/\/doi.org\/10.3389\/FONC.2020.00313\/REFERENCE","journal-title":"Front Oncol"},{"key":"4432_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25\u201335. https:\/\/doi.org\/10.1200\/JCO.2005.02.2194","journal-title":"J Clin Oncol"},{"key":"4432_CR7","doi-asserted-by":"publisher","unstructured":"Cella D, Kaiser K, Beaumont J, et al (2012) Quality of life (QOL) among renal cell carcinoma (RCC) patients in a randomized double blind cross-over patient preference study of pazopanib (P) versus sunitinib (S). Ann Oncol 23:ix261\u2013ix262. https:\/\/doi.org\/10.1016\/s0923-7534(20)33447-5","DOI":"10.1016\/s0923-7534(20)33447-5"},{"key":"4432_CR8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/J.CLGC.2015.01.007","volume":"13","author":"S Noda","year":"2015","unstructured":"Noda S, Otsuji T, Baba M et al (2015) Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma. Clin Genitourin Cancer 13:350\u2013358. https:\/\/doi.org\/10.1016\/J.CLGC.2015.01.007","journal-title":"Clin Genitourin Cancer"},{"key":"4432_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/S00280-009-1170-Y","volume":"66","author":"BE Houk","year":"2010","unstructured":"Houk BE, Bello CL, Poland B et al (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66:357\u2013371. https:\/\/doi.org\/10.1007\/S00280-009-1170-Y","journal-title":"Cancer Chemother Pharmacol"},{"key":"4432_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/FTD.0000000000000663","volume":"42","author":"R Demlov\u00e1","year":"2020","unstructured":"Demlov\u00e1 R, Turjap M, Pe\u0161 O et al (2020) Therapeutic drug monitoring of sunitinib in gastrointestinal stromal tumors and metastatic renal cell carcinoma in adults\u2014a review. Ther Drug Monit 42:20\u201332. https:\/\/doi.org\/10.1097\/FTD.0000000000000663","journal-title":"Ther Drug Monit"},{"key":"4432_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/FTD.0000000000000004","volume":"36","author":"NAG Lankheet","year":"2014","unstructured":"Lankheet NAG, Knapen LM, Schellens JHM et al (2014) Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Ther Drug Monit 36:326\u2013334. https:\/\/doi.org\/10.1097\/FTD.0000000000000004","journal-title":"Ther Drug Monit"},{"key":"4432_CR12","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/J.EJCA.2009.02.011","volume":"45","author":"S George","year":"2009","unstructured":"George S, Blay JY, Casali PG et al (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:1959\u20131968. https:\/\/doi.org\/10.1016\/J.EJCA.2009.02.011","journal-title":"Eur J Cancer"},{"key":"4432_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4103\/0019-509X.118725","volume":"50","author":"VM Krishna","year":"2013","unstructured":"Krishna VM, Noronha V, Prabhash K et al (2013) Sunitinib in metastatic renal cell carcimoma: a single-center experience. Indian J Cancer 50:268\u2013273. https:\/\/doi.org\/10.4103\/0019-509X.118725","journal-title":"Indian J Cancer"},{"key":"4432_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4155\/BIO-2019-0188","volume":"12","author":"M Gurjar","year":"2020","unstructured":"Gurjar M, Mehta P, Sharma J et al (2020) An HPLC method for simultaneous quantification of sunitinib and its active metabolite, SU12662, using hydrophilic interaction chromatography principle. Bioanalysis 12:75\u201385. https:\/\/doi.org\/10.4155\/BIO-2019-0188","journal-title":"Bioanalysis"},{"key":"4432_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/J.EJCA.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/J.EJCA.2008.10.026","journal-title":"Eur J Cancer"},{"key":"4432_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/J.CLGC.2014.06.015","volume":"12","author":"ID Schnadig","year":"2014","unstructured":"Schnadig ID, Hutson TE, Chung H et al (2014) Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices. Clin Genitourin Cancer 12:413\u2013421. https:\/\/doi.org\/10.1016\/J.CLGC.2014.06.015","journal-title":"Clin Genitourin Cancer"},{"key":"4432_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/CAD.0B013E3283442039","volume":"22","author":"A Ravaud","year":"2011","unstructured":"Ravaud A, Bello CL (2011) Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice. Anticancer Drugs 22:377\u2013383. https:\/\/doi.org\/10.1097\/CAD.0B013E3283442039","journal-title":"Anticancer Drugs"},{"key":"4432_CR18","unstructured":"Mendel DB, Douglas Laird A, Xin X, et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship."},{"key":"4432_CR19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/JJCO\/HYP146","volume":"40","author":"H Uemura","year":"2010","unstructured":"Uemura H, Shinohara N, Yuasa T et al (2010) A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 40:194\u2013202. https:\/\/doi.org\/10.1093\/JJCO\/HYP146","journal-title":"Jpn J Clin Oncol"},{"issue":"23","key":"4432_CR20","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/S10147-018-1302-7","volume":"235","author":"S Takasaki","year":"2018","unstructured":"Takasaki S, Kawasaki Y, Kikuchi M et al (2018) Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma. Int J Clin Oncol 235(23):936\u2013943. https:\/\/doi.org\/10.1007\/S10147-018-1302-7","journal-title":"Int J Clin Oncol"},{"key":"4432_CR21","doi-asserted-by":"publisher","unstructured":"Zhang AY, Fox P, Coulter S, et al (2014) Effect of toxicity-adjusted dose (TAD) of sunitinib on intra-patient variation of trough levels: a longitudinal study in metastatic renal cell cancer (mRCC) 32:2597\u20132597. https:\/\/doi.org\/10.1200\/JCO.2014.32.15_SUPPL.2597","DOI":"10.1200\/JCO.2014.32.15_SUPPL.2597"},{"key":"4432_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/CPT.787","volume":"102","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Yu H, Schellens JHM et al (2017) Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 102:765\u2013776. https:\/\/doi.org\/10.1002\/CPT.787","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04432-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04432-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04432-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T05:04:03Z","timestamp":1653541443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04432-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["4432"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04432-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.163638457.72181486\/v1","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"assertion":[{"value":"17 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (TMC-ACTREC IEC-III, Registration number: ECR\/149\/Inst\/MH\/2013) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent to participate in the study was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}